Amylyx Pharmaceuticals
AMLX
AMLX
170 hedge funds and large institutions have $1.08B invested in Amylyx Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 48 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less capital invested
Capital invested by funds: $1.18B → $1.08B (-$97.7M)
17% less call options, than puts
Call options by funds: $31.6M | Put options by funds: $38.2M
Holders
170
Holding in Top 10
5
Calls
$31.6M
Puts
$38.2M
Top Buyers
| 1 | +$25.5M | |
| 2 | +$23.1M | |
| 3 | +$21.3M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.1M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$16.2M |
Top Sellers
| 1 | -$40M | |
| 2 | -$22.7M | |
| 3 | -$22.1M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.9M |
| 5 |
D.E. Shaw & Co
New York
|
-$15.2M |